A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Atezolizumab; Cyclophosphamide; Fludarabine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZUMA-6
  • Sponsors Kite Pharma
  • Most Recent Events

    • 12 Dec 2017 Results of phase I of the study (n=6; data cutoff: June 23, 2017) assessing safety and efficacy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Aug 2017 According to a Kite Pharma media release, the preliminary data from this study is expected in the second half 2017.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top